BioWorld - Saturday, April 25, 2026

Neurology/psychiatric
Neurology/psychiatric RSS Feed RSS

Neurology/psychiatric

DYRK1A inhibitors for treating Alzheimer’s disease presented at ACS Spring

April 4, 2025
Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) is an attractive therapeutic target due to its involvement in cancer and neurodegenerative diseases. Researchers from the National Health Research Institutes and their collaborators have presented a series of DYRK1A inhibitors for reducing neurofibrillary tangle formation  in Alzheimer’s disease.
Read More

Sumitomo Pharma offloads two more subsidiaries

April 3, 2025
By Marian (YoonJee) Chu
Sumitomo Pharma Co. Ltd. announced that it will sell off two more of its subsidiaries, Sumitomo Pharma (China) Co. Ltd. and Sumitomo Pharma Asia Pacific Pte. Ltd. (and their subsidiaries), to Marubeni Global Pharma Corp. April 1, as the Japanese pharma continues restructuring efforts from last year.
Read More
Neurology/psychiatric

New SARM1 inhibitors disclosed in Tenvie patents

April 3, 2025
Tenvie Therapeutics Inc. has divulged NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors reported to be useful for the treatment of glaucoma, spinal cord injury, multiple sclerosis, Niemann-Pick disease, Alzheimer’s disease, amyotrophic lateral sclerosis, stroke and diabetic neuropathy, among others.
Read More
Neurology/psychiatric

New preclinical data on NKCC1 inhibitor IAMA-6 in neurological disorder models

April 3, 2025
Growing evidence exists on regulation of the chloride importer solute carrier family 12 member 2 (SLC12A2), also known as NKCC1, as a therapeutic approach to treat neurological disorders. Altered expression of NKCC1 leads to impaired intracellular chloride levels in neurons and imbalance in the excitatory-inhibitory axis in the brain.
Read More
Neurology/psychiatric

STM-003’s multifunctional efficacy delays AD progression, restores cognitive function in AD mice

April 3, 2025
At this week’s International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders, researchers from Suntec Medical Inc. and collaborators presented a poster introducing a novel biologic (STM-003) targeting several pathological mechanisms involved in Alzheimer’s disease (AD), aiming to delay disease progression and improve cognitive function.
Read More
Illustration of Microglia cells (red) in Alzheimer´s disease
Neurology/psychiatric

ADPD 2025: Emerging strategies fueling Alzheimer’s disease research

April 3, 2025
By Coia Dulsat
During the first oral sessions on Translational Drug Discovery at the 19th Alzheimer’s & Parkinson’s Diseases (ADPD) Conference, Beka Solomon from Tel Aviv University presented her work on the therapeutic potential of bone-marrow-derived microglia in Alzheimer’s disease (AD). “After working more than 30 years in immunotherapy, I decided to totally change the subject of the work,” Solomon told the audience.
Read More